Call for Papers  

Article Details


Inhibition of P450 17 as a New Strategy for the Treatment of Prostate Cancer

[ Vol. 12 , Issue. 14 ]

Author(s):

F. Leroux   Pages 1623 - 1629 ( 7 )

Abstract:


The cytochrome P450 monooxygenase enzyme system is involved in the synthesis and/or degradation of a large number of endogenous compounds and in the biotransformation of drugs and other xenobiotics. 17α-Hydroxylase-C17,20-lyase (P450 17, CYP 17) is the key enzyme of the androgen biosynthesis. As androgens have been implicated in the development and progression of prostate cancer, this enzyme has become a promising therapeutic target. This paper will review the possible approaches dealing with P450 17 inhibition as a chemotherapeutic strategy in the struggle against prostate cancer.

Keywords:

androgen,hydroxylase-c,lyase,cyp,prostate cancer,steroidal inhibitors,non-steroidal inhibitors,abiraterone,liarozole

Affiliation:

Laboratoire de Stereochimie associe au CNRS (UMR CNRS 7509), Universite Louis Pasteur (ECPM), 25 rue Becquerel, F- 67087 Strasbourg Cedex 2, France.



Read Full-Text article